Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA)
NCT05517603Phase 2Completed
- Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal and bulbar muscular atrophy (SBMA) comparing AJ201 with Placebo Comparator (2 arms). Primary endpoint: Incidence and proportion of subjects with AEs including SAEs and TEAEs at 12 weeks. Started Feb 2023; status: completed.
02
Drugs
rosolutamide
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on NCT05517603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517603.